CMP
GTBP icon

Coston McIsaac & Partners’s GT Biopharma GTBP Stock Holding History

Coston McIsaac & Partners’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8K Hold
17,092
– – ﹤0.01% 615
2026
Q1 		$6K Hold
17,092
– – ﹤0.01% 658
2025
Q4 		$13K Buy
+17,092
New +$12.1K ﹤0.01% 536

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM

Coston McIsaac & Partners's GTBP Position: Q2 2026 in Review

Coston McIsaac & Partners held its GT Biopharma (GTBP) position steady in Q2 2026 at 17,092 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #615.

Coston McIsaac & Partners first reported a position in GTBP in Q4 2025 and has held it in 3 quarters since. The position peaked at $13K in Q4 2025. 59 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • Coston McIsaac & Partners held 17,092 shares of GT Biopharma worth $8K as of Q2 2026.
  • Coston McIsaac & Partners left its GT Biopharma share count unchanged in Q2 2026.
  • GT Biopharma made up ﹤0.01% of Coston McIsaac & Partners's portfolio in Q2 2026, its #615 holding.
  • Coston McIsaac & Partners first reported a position in GT Biopharma in Q4 2025 and has held it in 3 quarters since.
  • Coston McIsaac & Partners's GT Biopharma position peaked at $13K in Q4 2025.
  • 59 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Coston McIsaac & Partners's 13F filing for Q2 2026, filed 12 Aug 2026.